On February 5, 2008, Pharmexa received information from H. Lundbeck A/S that H.
Lundbeck A/S has increased their holdings of Pharmexa shares from 40,000 to
4,974,061 shares, corresponding to 8.33% of the shares in Pharmexa A/S.
Hørsholm, February 5, 2008
Jakob Schmidt
Chief Executive Officer
Additional information:
Jakob Schmidt, Chief Executive Officer, tel +45 4516 2525
Claude Mikkelsen, Vice President, Corporate Affairs and Communication, tel +45
4516 2525 or +45 4060 2558
For the editors: Pharmexa A/S is a leading company in the field of active
immunotherapy and vaccines for the treatment of cancer and serious chronic and
infectious diseases. Pharmexa's proprietary technology platforms are broadly
applicable, allowing the company to address critical targets in cancer,
arthritis, bone degeneration and Alzheimer's disease, as well as infectious
diseases such as HIV, influenza, hepatitis and malaria. Company programs
include GV1001, a peptide vaccine that has entered Phase III trials in
pancreatic cancer and Phase II trials in liver cancer, and a number of HIV and
hepatitis vaccines in Phase I/II. Collaborative agreements include H. Lundbeck,
Innogenetics, IDM Pharma and Bavarian Nordic. With operations in Denmark,
Norway and USA, Pharmexa employs approximately 105 employees and is listed on
the OMX Nordic Stock Exchange Copenhagen under the trading symbol PHARMX.
